日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

癌症免疫治疗学会 (SITC) 关于肿瘤内免疫治疗临床试验 (IICT) 的建议:从癌前病变到转移性疾病

Luke, Jason J; Davar, Diwakar; Andtbacka, Robert H; Bhardwaj, Nina; Brody, Joshua D; Chesney, Jason; Coffin, Robert; de Baere, Thierry; de Gruijl, Tanja D; Fury, Matthew; Goldmacher, Gregory; Harrington, Kevin J; Kaufman, Howard; Kelly, Ciara M; Khilnani, Anuradha D; Liu, Ke; Loi, Sherene; Long, Georgina V; Melero, Ignacio; Middleton, Mark; Neyns, Bart; Pinato, David J; Sheth, Rahul A; Solomon, Stephen B; Szapary, Philippe; Marabelle, Aurelien

Ageing and endothelium-mediated vascular dysfunction: the role of the NADPH oxidases

衰老和内皮介导的血管功能障碍:NADPH 氧化酶的作用

Oh Sung Kwon, Sung Gi Noh, Soung Hun Park, Robert H I Andtbacka, John R Hyngstrom, Russell S Richardson

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study

OrienX010(一种溶瘤病毒)治疗不可切除的IIIC-IV期黑色素瘤患者:一项Ib期研究

Cui, ChuanLiang; Wang, Xuan; Lian, Bin; Ji, Qing; Zhou, Li; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Yu, Jiayi; Li, Siming; Mao, Lili; Tang, Bixia; Dai, Jie; Yan, Xieqiao; Bai, Xue; Andtbacka, Robert; Guo, Jun

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

肿瘤内溶瘤病毒V937联合伊匹木单抗治疗晚期黑色素瘤患者:1b期MITCI研究

Curti, Brendan D; Richards, Jon; Hyngstrom, John R; Daniels, Gregory A; Faries, Mark; Feun, Lynn; Margolin, Kim A; Hallmeyer, Sigrun; Grose, Mark; Zhang, Yiwei; Li, Anlong; Andtbacka, Robert H I

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

口服生物利用度高的CXCR4拮抗剂Mavorixafor可增加黑色素瘤患者肿瘤微环境的免疫细胞浸润和炎症状态。

Andtbacka, Robert H I; Wang, Yan; Pierce, Robert H; Campbell, Jean S; Yushak, Melinda; Milhem, Mohammed; Ross, Merrick; Niland, Katie; Arbeit, Robert D; Parasuraman, Sudha; Bickley, Kris; Yeung, Cecilia Cs; Aicher, Lauri D; Smythe, Kimberly S; Gan, Lu

Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma

替索托利莫德联合伊匹木单抗可增强抗PD-1耐药黑色素瘤的肿瘤反应

Cara Haymaker,Daniel H Johnson,Ravi Murthy,Salah-Eddine Bentebibel,Marc I Uemura,Courtney W Hudgens,Houssein Safa,Marihella James,Robert H I Andtbacka,Douglas B Johnson,Montaser Shaheen,Michael A Davies,Shah Rahimian,Srinivas K Chunduru,Denái R Milton,Michael T Tetzlaff,Willem W Overwijk,Patrick Hwu,Nashat Gabrail,Sudhir Agrawal,Gary Doolittle,Igor Puzanov,Joseph Markowitz,Chantale Bernatchez,Adi Diab

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

一项针对术后复发风险高的黑色素瘤患者的多中心、双盲、安慰剂对照试验,研究了seviprotimut-L多价黑色素瘤疫苗的疗效。

Craig L Slingluff,Karl D Lewis,Robert Andtbacka,John Hyngstrom,Mohammed Milhem,Svetomir N Markovic,Tawnya Bowles,Omid Hamid,Leonel Hernandez-Aya,Joel Claveau,Sekwon Jang,Prejesh Philips,Shernan G Holtan,Montaser F Shaheen,Brendan Curti,William Schmidt,Marcus O Butler,Juan Paramo,Jose Lutzky,Arvinda Padmanabhan,Sajeve Thomas,Daniel Milton,Andrew Pecora,Takami Sato,Eddy Hsueh,Suprith Badarinath,John Keech,Sujith Kalmadi,Pallavi Kumar,Robert Weber,Edward Levine,Adam Berger,Anna Bar,J Thaddeus Beck,Jeffrey B Travers,Catalin Mihalcioiu,Brian Gastman,Peter Beitsch,Suthee Rapisuwon,Vinay Gupta,Deepti Behl,Brent Blumenstein,Joanna J Peterkin

BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB

BRAFV600E通过microRNA介导的AURKB抑制,诱导人黑素细胞发生可逆性有丝分裂停滞。

Andrew S McNeal ,Rachel L Belote ,Hanlin Zeng ,Marcus Urquijo ,Kendra Barker ,Rodrigo Torres ,Meghan Curtin ,A Hunter Shain ,Robert Hi Andtbacka ,Sheri Holmen ,David H Lum ,Timothy H McCalmont ,Matt W VanBrocklin ,Douglas Grossman ,Maria L Wei ,Ursula E Lang ,Robert L Judson-Torres

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

TLPLDC疫苗作为III/IV期黑色素瘤手术切除后辅助治疗的IIb期随机对照试验:初步分析

Vreeland, Timothy J; Clifton, Guy T; Hale, Diane F; Chick, Robert C; Hickerson, Annelies T; Cindass, Jessica L; Adams, Alexandra M; Bohan, Phillip M Kemp; Andtbacka, Robert H I; Berger, Adam C; Jakub, James W; Sussman, Jeffrey J; Terando, Alicia M; Wagner, Thomas; Peoples, George E; Faries, Mark B

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST

实体瘤瘤内免疫治疗疗效评价标准:itRECIST

Goldmacher, Gregory V; Khilnani, Anuradha D; Andtbacka, Robert H I; Luke, Jason J; Hodi, F Stephen; Marabelle, Aurelien; Harrington, Kevin; Perrone, Andrea; Tse, Archie; Madoff, David C; Schwartz, Lawrence H